96 related articles for article (PubMed ID: 31683174)
1. Should we favour the use of 5 × 5 preoperative radiation in rectal cancer.
Kane C; Glynne-Jones R
Cancer Treat Rev; 2019 Dec; 81():101908. PubMed ID: 31683174
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Short- Vs. Long-Course Radiation for Locally Advanced Rectal Cancer: How to Choose.
Willett CG; Acklin-Wehnert S
Curr Treat Options Oncol; 2024 Apr; 25(4):427-433. PubMed ID: 38386240
[TBL] [Abstract][Full Text] [Related]
3. Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer.
Kim HS; Kim NK
Ann Gastroenterol Surg; 2020 Jul; 4(4):379-385. PubMed ID: 32724881
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced rectal cancer: The past, present, and future.
Oronsky B; Reid T; Larson C; Knox SJ
Semin Oncol; 2020 Feb; 47(1):85-92. PubMed ID: 32147127
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice.
Bregni G; Akin Telli T; Camera S; Deleporte A; Moretti L; Bali AM; Liberale G; Holbrechts S; Hendlisz A; Sclafani F
Cancer Treat Rev; 2020 Feb; 83():101948. PubMed ID: 31955069
[TBL] [Abstract][Full Text] [Related]
6. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
van der Valk MJM; Marijnen CAM; van Etten B; Dijkstra EA; Hilling DE; Kranenbarg EM; Putter H; Roodvoets AGH; Bahadoer RR; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes AMR; de Groot DJA; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Radiother Oncol; 2020 Jun; 147():75-83. PubMed ID: 32240909
[TBL] [Abstract][Full Text] [Related]
7. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
8. Should Short-Course Neoadjuvant Radiation Therapy Be Applied for Low-Lying Rectal Cancer? A Systematic Review and Meta-Analysis of the Randomized Trials.
Socha J; Kairevice L; Kępka L; Michalski W; Spałek M; Paciorek K; Bujko K
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1257-1264. PubMed ID: 32634546
[TBL] [Abstract][Full Text] [Related]
9. The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 ×5 Gy) in rectal cancer - are we too eager for surgery?
Glynne-Jones R; Hall M; Nagtegaal ID
Cancer Treat Rev; 2020 Nov; 90():102104. PubMed ID: 33002819
[TBL] [Abstract][Full Text] [Related]
10. Current and future cancer staging after neoadjuvant treatment for solid tumors.
Byrd DR; Brierley JD; Baker TP; Sullivan DC; Gress DM
CA Cancer J Clin; 2021 Mar; 71(2):140-148. PubMed ID: 33156543
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Giunta EF; Bregni G; Pretta A; Deleporte A; Liberale G; Bali AM; Moretti L; Troiani T; Ciardiello F; Hendlisz A; Sclafani F
Cancer Treat Rev; 2021 May; 96():102177. PubMed ID: 33798955
[TBL] [Abstract][Full Text] [Related]
12. Interpreting the RAPIDO trial: factors to consider - Authors' reply.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP
Lancet Oncol; 2021 Mar; 22(3):e90-e91. PubMed ID: 33662297
[No Abstract] [Full Text] [Related]
13. Interpreting the RAPIDO trial: factors to consider.
Kumar NAN
Lancet Oncol; 2021 Mar; 22(3):e86. PubMed ID: 33662294
[No Abstract] [Full Text] [Related]
14. Interpreting the RAPIDO trial: factors to consider.
Glynne-Jones R
Lancet Oncol; 2021 Mar; 22(3):e85. PubMed ID: 33662293
[No Abstract] [Full Text] [Related]
15. RAPIDO protocol: a promising approach for high-risk locally advanced rectal cancers.
Saklani A; Pandey D; Patel S
Lancet Oncol; 2021 Jan; 22(1):2-3. PubMed ID: 33301739
[No Abstract] [Full Text] [Related]
16. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E; Schlenska-Lange A; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Kirste S; Jacobasch L; Allgäuer M; Flentje M; Germer CT; Grützmann R; Hildebrandt G; Schwarzbach M; Bechstein WO; Sülberg H; Friede T; Gaedcke J; Ghadimi M; Hofheinz RD; Rödel C;
JAMA Oncol; 2022 Jan; 8(1):e215445. PubMed ID: 34792531
[TBL] [Abstract][Full Text] [Related]
17. Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits?
Aschele C; Glynne-Jones R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174033
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
19. Short-course radiotherapy for rectal cancer: real-world evidence in Argentina.
Tissera NS; Freile B; Waisberg F; Esteso F; Galli M; Loria FS; Luca R; Pedraza II; Enrico DH; Chacón C; Huertas E; Chacón MR; O'Connor JM
Ecancermedicalscience; 2023; 17():1555. PubMed ID: 37396101
[TBL] [Abstract][Full Text] [Related]
20. The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer.
Devlin L; Grocutt L; Hunter B; Chemu H; Duffton A; McDonald A; Macleod N; McLoone P; O'Cathail SM
Clin Transl Radiat Oncol; 2022 Sep; 36():24-30. PubMed ID: 35756193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
